Research and Markets: Biologics in the Emerging Markets: Ripe for Realization of the Commercial Potential - But Hurdles Still to Overcome

Research and Markets announces the addition of this report which has been written to support corporate strategy, new product development, business development, R&D, and brand teams through its analysis of the biologic trends being seen and the innovations taking place in this high growth market place.

(PRWEB) February 21, 2013

Research and Markets has announced the addition of the "Biologics in the Emerging Markets: Ripe for Realization of the Commercial Potential - But Hurdles Still to Overcome" report to their offering.

Biologics cover a diverse range of products and deliverables and have revolutionized the treatment of many diseases. The complexity of biologics has made their manufacturing process, an expensive and lengthy process which has hindered uptake in many less developed healthcare markets. However, the global biologics market is rapidly growing and was estimated to be worth over $130 billion in 2010.

Of the emerging markets, the BRIC markets offer the greatest potential for pharmaceutical growth, especially in biologics which represent a relatively untapped market in these countries. It is expected the BRIC markets will account for over 25% of global biologic revenues by 2015.

The report, Biologics in the Emerging Markets: Ripe for Realization of the Commercial Potential - But Hurdles Still to Overcome has been written to support corporate strategy, new product development, business development, R&D, and brand teams through its analysis of the biologic trends being seen and the innovations taking place in this high growth market place. This report will support the corporate strategies and key decisions being made around emerging market expansion, and future opportunities, and the challenges, which exist.

Key Reasons to Purchase

Use this report to understand how the biologics market is expected to develop in the emerging markets and the key growth drivers behind the forecasted changes

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/2/prweb10454694.htm

This report provides an overview of the current biologics landscape in each of the BRIC markets, along with expected challenges and potential areas of growth in the near term

Understand how key factors, such as diagnostic testing, high price points and negative perceptions of biologics, are hindering their wider use in some emerging markets

Benefit from CBR's in-depth analysis of the competitive landscape for biologics in the BRIC markets, including recent activities of both local and multinational companies and the prospects for collaboration moving forward

Access our assessment of how biosimilars are boosting the biologics sector within emerging markets and why they have been so quick to take off in these regions compared to the US and EU market

Key Topics Covered:

Executive summary

Methodology

Biologics overview

Biologics in emerging markets - key facts

Key challenges to greater use of biologics in the emerging markets

Who are the key biologics players in emerging markets?

Appendix

For more information visit http://www.researchandmarkets.com/research/4lrpxl/biologics_in_the

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716